Avantor, Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Avantor, Inc. (NYSE: AVTR) is a leading global provider of mission-critical products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries; the company offers a broad portfolio encompassing materials and consumables such as ultra-high purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, process chromatography resins and columns, analytical sample prep kits, education and microbiology kits, and clinical trial kits; equipment and instrumentation including filtration systems, virus inactivation systems, incubators, peristaltic pumps, fluid handling tips, and analytical instruments; and services and specialty procurement such as onsite lab and production services, equipment procurement and sourcing, biopharmaceutical material scale-up and development, procurement and material management, general lab services, technical lab services, production services, downstream optimization, and business process consulting. Operating through two primary segments—Laboratory Solutions and Bioscience Production—Avantor supports applications in monoclonal antibodies, recombinant proteins, gene therapies, vaccines, cell therapies, mRNA vaccines and therapies, fluid handling technologies, buffer management, and small molecule products, with a global footprint spanning over 30 countries across the Americas, Europe, and AMEA regions and access to more than 300,000 customer locations. Founded in 1904 and headquartered in Radnor, Pennsylvania, the company maintains an integrated business model with extensive manufacturing, distribution, and sales centers worldwide. Recent developments include the appointment of Emmanuel Ligner as President and CEO to drive growth and value creation in life sciences; divestiture of its clinical services business to Audax Private Equity for $650 million in 2025, rebranded as Resonant Clinical Solutions, to sharpen focus on lab and production businesses while generating approximately $500 million in after-tax cash proceeds for debt reduction; expansion of centralized service center model with a new Boston-area facility featuring specialized glassware washing and autoclaving; a strategic partnership with p-Chip Corporation announced in October 2025 to develop solutions for secure chain-of-identity, enhanced traceability, and digital process control in pharmaceutical and clinical manufacturing; and a significant capacity expansion at its European manufacturing site to quadruple production for biologics and therapies.
Company News
Why Is Avantor (AVTR) Up 5.4% Since Last Earnings Report?
Is Avantor a Buy as Revival Progress Faces Persistent Margin Pressure?
Callan Family Office LLC Invests $2.02 Million in Avantor, Inc. $AVTR
Advisors Capital Management LLC Invests $4.37 Million in Avantor, Inc. $AVTR
Is Avantor (AVTR) Outperforming Other Medical Stocks This Year?
Are Medical Stocks Lagging Avantor (AVTR) This Year?
Avantor, Inc. (AVTR) Just Flashed Golden Cross Signal: Do You Buy?
Bank of Nova Scotia Has $326,000 Stock Holdings in Avantor, Inc. $AVTR
Avantor Q2 Earnings Beat Estimates on VWR Growth, Guidance Raised
Avantor (NYSE:AVTR) Shares Gap Up Following Earnings Beat
Avantor Q2 Earnings Call Highlights
Oil Spikes 7%, Nasdaq 100 Sinks Before Fed: Stock Market Today
Avantor, Inc. (AVTR) Q2 2026 Earnings Call Transcript
Avantor (AVTR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Avantor, Inc. (AVTR) Beats Q2 Earnings and Revenue Estimates
Avantor® Reports Second Quarter 2026 Results
Avantor, Inc. (AVTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
AVTR vs. ICLR: Which Stock Should Value Investors Buy Now?
Will Avantor (AVTR) Beat Estimates Again in Its Next Earnings Report?
Avantor Stock Up on NuSil's Expanded HIV Prevention Partnership